Skip to main content
SEOUL PHARMA CO.,LTD logo

SEOUL PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 018680 ISIN · KR7018680009 KO Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2024-03-13 AGM Information
Country KR South Korea
Listing KO 018680

About SEOUL PHARMA CO.,LTD

http://www.seoulpharmaceuticals.com/

Seoul Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in innovative drug delivery systems, with a core competency in Orally Disintegrating Film (ODF) technology. Its product portfolio includes a wide range of prescription and over-the-counter medications. Key therapeutic areas cover cardiovascular and respiratory systems, as well as anti-infective agents such as antibacterials, antifungals, and antivirals. The company also produces vitamins and antibiotics, aiming to improve health outcomes through its cutting-edge technological capabilities.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Seoul Pharma. It outlines the date, location, agenda items (such as financial statement approval and director re-election), and board resolution details. This document serves as the official proxy solicitation and meeting notice sent to shareholders to inform them of the upcoming AGM and request their participation/votes. Therefore, it fits the definition of a Proxy Solicitation & Information Statement.
2024-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Seoul Pharma. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, re-election of directors, and remuneration limits. It also includes detailed financial statements (Balance Sheet, Income Statement, Statement of Appropriation of Retained Earnings) and management information (Board activities, business overview). This type of document is a standard Proxy Solicitation & Information Statement (PSI) used to inform shareholders of meeting details and request their votes.
2024-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Seoul Pharma) announcing a significant change (over 30%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard 'Earnings Release' (ER) format used in the Korean market to provide preliminary financial results before the final audited annual report is published. It contains key financial highlights and the reasons for the variance, fitting the definition of an Earnings Release. FY 2023
2024-02-02 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a formal notice from Seoul Pharma regarding the setting of a record date and the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the 38th Annual General Meeting. This type of regulatory disclosure, which informs the market about administrative procedures related to shareholder meetings, is classified as a general regulatory filing.
2023-12-14 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Seoul Pharma, covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial data, business operations, management discussions, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
불성실공시법인미지정(지정유예)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory announcement from the Korea Exchange regarding the status of Seoul Pharma as a 'non-designated' entity for unfair disclosure practices. It details the decision date, the reasoning for non-designation (deferral), and references specific KOSDAQ market disclosure regulations. As this is a regulatory notice regarding compliance and disclosure status rather than a financial report or corporate action, it falls under the general regulatory filing category.
2023-08-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.